(3S)-1-(Cyclopropylmethyl)-3-methylpiperazine | 923944-13-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (3S)-1-(Cyclopropylmethyl)-3-methylpiperazine
• 英文别名: (3S)-1-(cyclopropylmethyl)-3-methylpiperazine
• CAS: 923944-13-2
• 化学式: C₉H₁₈N₂
• 分子量: 154.25
• InChiKey: IWRIBHLFZPQASA-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof
  申请人：Ontario Institute for Cancer Research (OICR)

  公开号：US11242351B2

  公开（公告）日：2022-02-08

  The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及式（I）化合物或其药学上可接受的盐、溶液剂和/或原药，涉及包含这些化合物或其药学上可接受的盐、溶液剂和/或原药的组合物，以及在治疗可通过抑制与 BCL6 BTB 的相互作用来治疗的疾病、失调或病症（如癌症）中的各种用途。
• Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction
  申请人：Ontario Institute for Cancer Research (OICR)

  公开号：US11518764B2

  公开（公告）日：2022-12-06

  The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及式 I 化合物 或其药学上可接受的盐、溶液剂和/或原药，涉及包含这些化合物或其药学上可接受的盐、溶液剂和/或原药的组合物，以及在治疗可通过抑制与 BCL6 BTB 的相互作用来治疗的疾病、失调或病症（如癌症）中的各种用途。
• TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
  申请人：Ontario Institute for Cancer Research (OICR)

  公开号：EP3728267A1

  公开（公告）日：2020-10-28
• INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
  申请人：Ontario Institute for Cancer Research (OICR)

  公开号：US20200331921A1

  公开（公告）日：2020-10-22

  The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.